Better Therapeutics, Inc.
Better Therapeutics, Inc.
Your view on BTTX
Overview
What the company does, where it operates, and who runs it.
About Better Therapeutics, Inc.
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- David Perry
- Headquarters
- 548 Market Street, San Francisco, CA, US
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- David Perry
- Headquarters
- 548 Market Street, San Francisco, CA, US
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States.
Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes.
The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Better Therapeutics, Inc., and the rating behind it. BTTX last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Better Therapeutics, Inc.. Starting points for Better Therapeutics, Inc.: EPS -$1.69, beta 1.69 — an Medical - Specialties name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Better Therapeutics, Inc.. Better Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Better Therapeutics, Inc.. Trailing twelve-month EPS for Better Therapeutics, Inc. stands at -$1.69. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Better Therapeutics, Inc.. Better Therapeutics, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Better Therapeutics, Inc. valued side by side against its closest peers. Better Therapeutics, Inc. is measured against Medical - Specialties peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Better Therapeutics, Inc., and how their positions are changing. At a $5,452 market value, institutional positions materially move Better Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Better Therapeutics, Inc. executives and directors. Shares of Better Therapeutics, Inc. have traded between $0.0001 and $0.0010 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Better Therapeutics, Inc.. Better Therapeutics, Inc. is a $5,452 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Better Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Better Therapeutics, Inc.. Coverage tracks Better Therapeutics, Inc. within Medical - Specialties (Healthcare). Press releases and market coverage, newest first.